Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.56 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.55 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.55 |
| ▸ | ROS1 | P08922 | 1/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.55 |
| ▸ | CASP6 | P55212 | 2/20 | 0.53 |
| ▸ | TDP2 | O95551 | 1/20 | 0.53 |
| ▸ | CASP3 | P42574 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | CASP9 | P55211 | 1/20 | 0.53 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.53 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21000480 | 0.88 | MAOA (0.56) | CSNK1G1ACVR1LRRK2ROS1CDK5 | |
| SCHEMBL18020364 | 0.88 | CSNK1G1 (0.56) | CSNK1G1ACVR1LRRK2ROS1CDK5 | |
| SCHEMBL2087698 | 0.81 | TDP2 (0.66) | ACVR1LRRK2CASP6TDP2CASP3 | |
| SCHEMBL11537959 | 0.80 | ROS1 (0.47) | CSNK1G1ACVR1LRRK2ROS1CDK5 | |
| SCHEMBL11927570 | 0.77 | HTR5A (0.52) | CSNK1G1ACVR1LRRK2ROS1CDK5 | |
| SCHEMBL9670200 | 0.77 | CASP6 (0.51) | CSNK1G1ACVR1LRRK2ROS1CDK5 | |
| SCHEMBL6905673 | 0.75 | MAOA (0.67) | CASP6MAPTGAAALDH1A1NPC1 | |
| SCHEMBL433708 | 0.74 | AHR (0.61) | GAACYP1A2GRIA1CACNG8MAOB | |
| SCHEMBL31400232 | 0.74 | ALDH1A1 (0.59) | MAPTGAAALDH1A1NPC1CYP1A2 | |
| SCHEMBL1609497 | 0.74 | ALDH1A1 (0.59) | MAPTGAAALDH1A1NPC1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929688-B | 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders | 阿莱瑞恩公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-4048667-B1 | 3-(4-(11H-DIBENZO[B,E][1,4]AZEPIN-6-YL)PIPERAZIN-1-YL)- AND 3-(4-(DIBENZO[B,F][1,4]OXAZEPIN/THIAZEPIN/DIAZEPIN-11-YL)PIPERAZIN-1-YL)-PROPANOIC ACID DERIVATIVES AS H1 AND 5-HT2A-RECEPTOR MODULATORS FOR THE TREATMENT OF SLEEP DISORDERS | ALAIRION INC (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-114929688-A | 3- (4- (11H-dibenzo [ b, e ] [1,4] azepin-6-yl) piperazin-1-yl) -and 3- (4- (dibenzo [ b, f ] [1,4] oxazepin/thiazepin/diazepin-11-yl) piperazin-1-yl) -propionic acid derivatives as H1 and 5-HT 2A-receptor modulators for the treatment of sleep disorders | 阿莱瑞恩公司 | 2022-08-19 | — | — | CN | disclosed |
| US-11046651-B2 | Piperazine substituted azapine derivatives and uses thereof | ALAIRION, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-11046651-B2 | Piperazine substituted azapine derivatives and uses thereof | ALAIRION, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20210114989-A1 | PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF | Neumora Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
| US-20210114989-A1 | PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF | Neumora Therapeutics, Inc. | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046651-B2 | Piperazine substituted azapine derivatives and uses thereof | HTR2A, HTR5A, HTR2C | CSNK1G1 1967/4885ACVR1 1485/4885LRRK2 3945/4885 |
| US-20210114989-A1 | PIPERAZINE SUBSTITUTED AZAPINE DERIVATIVES AND USES THEREOF | HTR2A, HTR5A, HTR2C | CSNK1G1 1967/4885ACVR1 1485/4885LRRK2 3945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.